These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6736272)

  • 41. Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis.
    de Oliveira IR; de Sena EP; Pereira EL; Miranda AM; de Oliveira NF; Ribeiro MG; de Castro-e-Silva E; Dardennes RM; Samuel-Lajeunesse B; Marcilio C
    J Clin Pharm Ther; 1996 Aug; 21(4):229-36. PubMed ID: 8933296
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia.
    Rao VA; Bishop M; Coppen A
    Br J Psychiatry; 1980 Dec; 137():518-21. PubMed ID: 7214106
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Red blood cell/plasma haloperidol ratios and antipsychotic efficacy.
    Neborsky RJ; Janowsky DS; Perel JM
    Psychiatry Res; 1982 Feb; 6(1):123-4. PubMed ID: 6949166
    [No Abstract]   [Full Text] [Related]  

  • 44. Comparison of haloperidol plasma concentrations between twice-a-day and once-a-day dosing in Chinese schizophrenic patients.
    Lin SK; Chen CH; Chang WH
    J Formos Med Assoc; 1993 Sep; 92(9):832-4. PubMed ID: 7904867
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients.
    Moulin MA; Davy JP; Debruyne D; Andersson JC; Bigot MC; Camsonne R; Poilpré E
    Psychopharmacology (Berl); 1982; 76(4):346-50. PubMed ID: 6812109
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasma haloperidol levels and clinical response.
    Smith RC
    Arch Gen Psychiatry; 1987 Dec; 44(12):1110-2. PubMed ID: 3689100
    [No Abstract]   [Full Text] [Related]  

  • 47. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.
    Ulrich S; Wurthmann C; Brosz M; Meyer FP
    Clin Pharmacokinet; 1998 Mar; 34(3):227-63. PubMed ID: 9533984
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduced haloperidol/haloperidol ratio and clinical outcome in schizophrenia: preliminary evidences.
    Altamura C; Mauri M; Cavallaro R; Colacurcio F; Gorni A; Bareggi S
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(5):689-94. PubMed ID: 3222450
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is there a relationship between antipsychotic blood levels and their clinical efficacy? An analysis of studies design and methodology.
    de Oliveira IR; Dardennes RM; Amorim ES; Diquet B; de Sena EP; Moreira EC; de Castro-e-Silva EJ; Payan C; Fermanian J; Marcílio C
    Fundam Clin Pharmacol; 1995; 9(5):488-502. PubMed ID: 8617413
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantification of reduced haloperidol and haloperidol by radioimmunoassay.
    Browning JL; Harrington CA; Davis CM
    J Immunoassay; 1985; 6(1-2):45-66. PubMed ID: 4019788
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Haloperidol pharmacokinetics following gastric bypass surgery.
    Fuller AK; Tingle D; DeVane CL; Scott JA; Stewart RB
    J Clin Psychopharmacol; 1986 Dec; 6(6):376-8. PubMed ID: 3805335
    [No Abstract]   [Full Text] [Related]  

  • 52. Lithium and haloperidol.
    Nemes ZC; Volavka J; Cooper TB; O'Donnell J; Jaeger J
    Biol Psychiatry; 1986 May; 21(5-6):568-9. PubMed ID: 3697447
    [No Abstract]   [Full Text] [Related]  

  • 53. Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients.
    Rimón R; Averbuch I; Rozick P; Fijman-Danilovich L; Kara T; Dasberg H; Ebstein RP; Belmaker RH
    Psychopharmacology (Berl); 1981; 73(2):197-9. PubMed ID: 6785816
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Haloperidol plasma level monitoring in neuropsychiatric patients.
    Morselli PL; Bianchetti G; Dugas M
    Ther Drug Monit; 1982; 4(1):51-8. PubMed ID: 7041338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antipsychotic drugs and plasma vasopressin in normals and acute schizophrenic patients.
    Raskind MA; Courtney N; Murburg MM; Backus FI; Bokan JA; Ries RK; Dorsa DM; Weitzman RE
    Biol Psychiatry; 1987 Apr; 22(4):453-62. PubMed ID: 3567260
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Megabore capillary gas-liquid chromatographic method with nitrogen-phosphorus selective detection for the assay of haloperidol and reduced haloperidol in serum: results of therapeutic drug-monitoring during acute therapy of eight schizophrenics.
    Ulrich S; Meyer FP; Neuhof S; Knorr W
    J Chromatogr B Biomed Appl; 1995 Jan; 663(2):289-96. PubMed ID: 7735476
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia.
    Kidron R; Averbuch I; Klein E; Belmaker RH
    Biol Psychiatry; 1985 Feb; 20(2):219-22. PubMed ID: 3971003
    [No Abstract]   [Full Text] [Related]  

  • 58. Determination of haloperidol and reduced haloperidol in the plasma and blood of patients on depot haloperidol.
    Eyles DW; Whiteford HA; Stedman TJ; Pond SM
    Psychopharmacology (Berl); 1992; 106(2):268-74. PubMed ID: 1549652
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine.
    Garver DL; Dekirmenjian H; Davis JM; Casper R; Ericksen S
    Am J Psychiatry; 1977 Mar; 134(3):304-7. PubMed ID: 14514
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparison of dopamine receptor blocking assay with plasma drug levels of haloperidol in schizophrenic patients.
    Kurland AA; Nagaraju A; Hanlon TE; Wilkinson EH; Ng KT
    J Clin Pharmacol; 1981 Jan; 21(1):42-7. PubMed ID: 7217342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.